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Probabilistically Certified Region of Attraction of a Tumor
Growth Model with Combined Chemo- and Immunotherapy
Kaouther Moussa∗, Mirko Fiacchini∗ and Mazen Alamir∗
Abstract—This paper deals with the estimation of
regions of attraction (RoAs) under parametric un-
certainties for a cancer growth model with combined
therapies. We propose a framework of probabilistic
certification, based on the randomized methods, in
order to derive probabilistically certified RoAs of a
cancer growth model. The model that we consider in
this paper describes the interaction between tumor
and immune system in presence of a combined chemo-
and immunotherapy. Furthermore, we model the con-
centration of the chemotherapy agent in the body via
a pharmacokinetic equation.
I. Introduction
The last decades witnessed a considerable progress in
experimental and clinical immunology [8] as well as in
modeling the immune system dynamics.
The progress in cancer dynamics modeling motivated
researchers to apply control approaches in order to sched-
ule cancer treatments using optimal control strategies.
We can find in the literature many works regarding
the application of optimal control approaches on cancer
treatment problems. For instance [6], where optimal
protocols for anti-angiogenic therapy were investigated,
or [5] where linear controls were designed for a tumor-
immune interactions model with chemotherapy delivery.
However, only few works addressed the problem of han-
dling parametric uncertainties. One can cite for example,
[1] where a robust feedback scheme is proposed to sched-
ule antiangiogenic treatment combined with chemother-
apy, [9] where an H∞-based robust control was applied
to the same model and [2] where a general framework
for probabilistic certification of cancer therapies was
proposed.
The estimation of the region of attraction for cancer
models is an interesting problem since it provides a
set of possible initial conditions (tumor volume and
immune density for example) that can be driven to a
desired target set (benign region). This problem becomes
complex when dealing with nonlinear systems and even
more challenging for uncertain systems. There are some
works which dealt with the problem of estimating the
RoA for cancer models but only few of them considered
model uncertainties. In particular, in [12], an iterative
method to estimate the robust RoA was presented. How-
ever, robust RoA estimation is based on the worst-case
scenario analysis leading to very pessimistic design. This
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is because the worst case is considered no matter how
small its probability of occurrence is.
In this paper, we propose a framework to probabilis-
tically certify the existence of a control structure that
drives the states corresponding to tumor cells and im-
mune density from an initial state set to a certified target
set. This probabilistic certification framework is based on
the randomized methods proposed in [3] and [4], which,
unlike the robust classical design, avoids focusing on few
unlikely very bad scenarios allowing to overcome the
conservatism of the robust RoA design. The methodology
that we propose in this paper consists mainly of two
steps. Firstly, we derive an ordered sequence of sets and
a control strategy over each of them such that the states
can be driven from a set to the previous with a certain
probabilistic guarantee. The appropriate choice of the
first set allows to insure that the union of the sets is a
probabilistically certified approximation of the RoA. The
second step consists of providing a global certification
on the probability of convergence to the initial certified
target set.
This paper is organized as follows: In Section II,
the dynamical cancer model and the problem of RoA
probabilistic certification are introduced. In Section III,
a framework for RoA probabilistic certification is pro-
posed, based on the randomized methods presented in
[3] and [4]. In Section IV, the proposed RoA probabilis-
tic certification framework is applied to the considered
cancer model. Finally, Section V summarizes the contri-
bution and gives some hints for further investigation.
II. Problem statement
The following nonlinear dynamical system describes
the interaction between tumor and immune system in
presence of chemotherapy and immunotherapy drugs:
x˙1 = µCx1 −
µC
x∞
x21 − γx1x2 − σx1x3,
x˙2 = µIx1x2 − βx
2
1x2 − χx2 + λx2u2 − ̺x3x2 + α,
x˙3 = −ax3 + bu1,
x(0) = (x1(0), x2(0), x3(0)) = x0,
(1)
where x1, x2 and x3 denote, respectively, the number of
tumor cells, the density of effector immune cells (ECs)
and the concentration of chemotherapy in the body,
u1 and u2 are, respectively, the dosages of a cytotoxic
agent and an immuno-stimulator. This model gives the
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Fig. 1: Schematic representation of the different interactions in
model (1), between tumor, immune system and drug dosages.
advantage of a low dimensional system that nevertheless
includes the main aspects of cancer-immune interactions.
In many models it is assumed that the drug concentra-
tion is equal to its dosage which is an oversimplification.
Therefore, we revisited the model proposed in [7] by
adding a pharmacokinetic (PK) equation that allows to
model the concentration of chemotherapy in the body.
This equation is a classical PK model with an exponen-
tial growth/decay of the drug concentration.
Fig. 1 presents a scheme describing the different in-
teractions between the tumor and the immune system.
Table I summarizes the definitions of the model param-
eters and their numerical values. We slightly tuned the
values of some parameters since with the previous set of
parameters values (used in [11] and [10]), the domain of
attraction of the benign equilibrium for the uncontrolled
system (1) (for u1 = 0 and u2 = 0) was unrealistically
big, this allows us to solve a more challenging and
seemingly realistic problem. Moreover, we properly chose
the parameters a and b of the PK dynamics, such that
the drug concentration reaches its maximum in 4.8h and
starts decreasing towards a negligible value after a period
of 15 days. Nevertheless, it is worth emphasizing that in
this paper, we focus on the assessment of a methodology
that remains applicable for different nominal and PK
parameters values.
Let’s denote by x = (x1, x2, x3) and u = (u1, u2)
respectively, the state and the control input vectors. In
this paper, we consider a cycle-based treatment, where
the drugs are injected following NC therapeutic cycles,
each cycle has two phases, a hospitalization period where
the drugs are injected for 5 consecutive days and a
rest period where the patient recovers. Fig. 2 shows a
typical temporal combined control structure where the
time unit is in days, σI and dI stand for the duration and
the concentration level of the immunotherapy injection,
respectively. The chemotherapy is assumed to be delayed
from the immunotherapy by νC and is injected for σC
days with a concentration dC . T stands for the time
of the hospitalization period while Tc denotes the cycle
duration. Therefore, for a given treatment cycle, the
therapeutic profile considered in this paper is completely
defined by the following control parametrization θ:
TABLE I: Numerical values and definitions of the pa-
rameters used in model (1)
Parameter Definition Numerical value
µC tumor growth rate 1.0078 ·10
7 cells/day
µI tumor stimulated 0.0029 day
−1
proliferation rate
α rate of immune 0.0827 day−1
cells influx
β inverse threshold 0.0040
γ interaction rate 1 ·107 cells/day
χ death rate 0.1873 day−1
σ chemotherapeutic 1 ·107 cells/day
killing parameter
λ immunotherapy 1 ·107 cells/day
injection parameter
x∞ fixed carrying capacity 780 ·106 cells
̺ chemo-induced loss 1
on immune cells
a chemotherapy 0.5
concentration decay
b drug rate effect 1
on the concentration
of chemotherapy
Time1 2 3 4 TcT
dI
Drug dosage
Hospitalization Rest
σI
σC
dC
νC
Fig. 2: Temporal open-loop control structure for each cycle,
in black and yellow, respectively, the immunotherapy and the
chemotherapy profiles.
θ = [νC , σC , dC , σI , dI ]. (2)
In cancer treatment design, we usually have many
constraints to satisfy, they can be defined either on the
states or on the control inputs. These constraints enable
to prevent from drug toxicity and immune weakening.
Therefore, we consider the following constraints:{
x2(t) ≥ c, ∀t ∈ [0, T ] with c, T ∈ R+,
0 ≤ x3(t) ≤ 1, 0 ≤ u2(t) ≤ 1,
(3)
where the first constraint is a health constraint on the
minimal density of immune cells. The constraints on
x3(t) and u2(t) for all t, are drug toxicity constraints. The
constraint on x3 can be satisfied by properly choosing
a constraint on u1, given the PK parameters (a and b)
since these two variables are linked through a simple first
order dynamics. Fig. 3 shows a typical PK curve, where
5 consecutive doses of chemotherapy are injected, at a
rate of 1 dose per day, each dose lasts 4.8h. We can notice
that thanks to a proper choice of the constraint on u1, the
constraint on x3 is satisfied even for successive drug doses
injections. Furthermore, the constraints on the control
inputs, u1 and u2, can be satisfied by properly choosing
the parametrization θ of the control input u. Therefore,
we will consider only the first constraint on x2, since the
satisfaction of the other constraints can be monitored by
a proper choice of θ.
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Fig. 3: A typical PK curve for chemotherapy, where u1 represents
5 consecutive doses of 4.8h, during the 5 first days of the therapy
period, at a rate of one dose per day.
The uncontrolled model (1) (for u = (0, 0)) has two
locally asymptotically stable equilibria. The macroscopic
malignant equilibrium is xm = (766.4, 0.018, 0) and the
benign one is xb = (41.45, 0.954, 0). The objective of
the treatment is to drive the state initial conditions to
the region of attraction of the benign equilibrium (safe
region), without constraints violation. Therefore, we are
interested in characterizing the set of initial conditions
(tumor volume and immune density) from which the
trajectories of (1) can be driven to the safe region under
parametric uncertainties.
In this paper we aim at computing a sequence of sets
{Ωk}
NC
k=1, for NC therapeutic cycles. Those sets are deter-
mined in the space of the cancer burden and the ECs den-
sity, such that, in the family of control parametrizations
that we consider, there exists a therapeutic protocol that
drives, with a desired probability, the states from Ωk+1
to
k⋃
j=0
Ωj without safety constraints violations. The set
Ω0 is defined here as a probabilistically certified region
of attraction of the benign equilibrium, when no control
is applied i.e. u = 0. We denote by ΩN an estimation
of the region of attraction of the benign equilibrium for
u = 0, when nominal model parameters (in Table I) are
considered. Therefore, we propose a feedback strategy
that can be seen in an implicit way, such that at the end
of each therapy period, we measure the states (patient
health and tumor volume) and depending on the certified
set Ωk where this measure lies, we can estimate the
maximal possible recovery time (Tc−T ) that the patient
can take. At the end of the rest period, the certified
therapy corresponding to this set is then applied, we keep
doing this process until we reach the safe region Ω0.
III. RoA probabilistic certification using
randomized methods
In this section, we will establish a framework of
RoA probabilistic certification, based on the randomized
methods presented in [3] and [4]. Therefore, we will
briefly recall the main key-points of the randomized
approaches that are important for our RoA certification
framework. The Randomized methodology had been used
to certify feedback control strategies in [2] for a combined
cancer therapy model. In this paper, we propose to
use this general framework in order to probabilistically
certify the existence of a control structure which allows
to drive initial states from a given set to a target set
under parametric uncertainties.
Let’s rewrite system (1) into the following form:
x˙ = f(x, u, p), (4)
where p is the vector of parameters that model (1)
involves. Furthermore, we consider that the variables of
system (4) are subject to the following constraints:
x ∈ X, x(T ) ∈ Ω, u ∈ U. (5)
In this paper, we are interested in specific control struc-
tures, since in cancer treatment, control inputs cannot be
free real variables. They are usually defined by specific
cyclic protocols, as illustrated in the subsequent section.
Furthermore, in order to solve the optimization problem
that we will define in the sequel, using the randomized
methods, we need to consider that the control inputs are
parametrized by a vector θ which lies in a discrete set
Θ with cardinality nΘ ∈ N. However, this choice of θ
remains interesting in the case of cancer therapy design,
since some of the parameters involved in the treatment
scheduling are naturally quantified.
We consider that the parameters vector p is a random
variable following the probability distribution P that we
denote p ∼ P . Given a set Γ ⊆ Rn (to be more precise,
Γ must belong to the σ-algebra defined on Rn) and a
parameterization of the input θ ∈ Θ, let’s consider the
following optimization problem:
min
θ∈Θ
J(θ) s.t. ∀ (x0, p) ∈ (Γ× P) g(θ, x0, p) = 0,
(6)
where J(θ) is a cost function to be minimized. In terms
of cancer treatment design, this function can be a com-
bination of many objectives that one seeks to achieve,
for example reducing the quantity of injected drugs,
to prevent from toxicity, or reducing the duty cycle in
order to reduce the hospitalization duration. Whereas
g is the failure indicator function, defined on the state
trajectories of (4). The function g, in particular, is a
deterministic function that, for given initial state, input
parameter θ and model parameter p ∈ P, has value equal
to one if constraints (5) are violated, zero otherwise.
Problem (6), then, aims at selecting the optimal control
strategy such that no specification violation occurs.
The randomized method consists of replacing the orig-
inal problem in (6) by the following chance-constrained
problem allowing some violations:
min
θ∈Θ
J(θ) s.t. PrX0(Γ)×P {g(θ, x0, p) = 1} ≤ η, (7)
where the constraint is on the probability of constraints
violation, with respect to the distribution of x0 on Γ,
that we denote X0(Γ), and p ∼ P . This problem gives
therefore a chance constrained formulation in the sense
that we can accept a vector θ which minimizes the
cost J , even if the specifications are violated for some
realizations of (x0, p), provided that the probability of
these violations is lower than η hence small enough.
Since problem (7) is hard to solve, it can be simpli-
fied into the following problem, employing the empirical
mean instead of the probability of the constraints viola-
tion:
min
θ∈Θ
J(θ) s.t.
N∑
i=1
g
(
θ, x
(i)
0 , p
(i)
)
≤ m,
(x0, p)
(i) ∼ (X0(Γ)× P) , ∀i = 1, . . . , N,
(8)
where m is the maximum number of constraints viola-
tion.
Theorem 1: For given Γ ⊆ Rn, let m ∈ N be any
integer, let δ ∈ (0, 1) be a targeted precision parameter,
and suppose that problem (8) has a solution, that we
denote θˆ, for N i.i.d. samples of (x0, p), with N satisfying
the following condition from [4]:
N ≥
1
η
(
m+ ln
(nΘ
δ
)
+
(
2m ln
(nΘ
δ
)) 1
2
)
Then the solution θˆ satisfies the constraint in problem
(7) with a probability higher than 1− δ.
It is interesting to notice that the bound on N in
Theorem 1 provided by [4] does not depend on the
dimension of the vector (x0, p) which is useful when
having many uncertain parameters and initial states in
the certification problem. Furthermore, the confidence
parameter δ affects the bound with a logarithmic term
which means that we can have a highly confident certi-
fication with a tractable number of random samples.
Therefore, the iterative resolution of problems of the
type (8) allows one to generate a sequence of sets
{Ωk}
NC
k=1 such that the constraints violation on passing
from Ωk+1 to
k⋃
j=0
Ωj is smaller then η with a certain
desired confidence probability 1− δ.
A. Algorithm for RoA estimation
Given a target set Ω, let’s suppose that our objective is
to certify that the set Γ is such that there exists a control
parametrization θ, for which at least 100 · (1 − η)% of
the trajectories of (4), generated by the distributions of
the initial states x0 ∈ Γ and the uncertain parameters
p, converge to Ω at time T , while satisfying constraints
(5), with a probability of confidence higher than 1 − δ.
Any solution of (8) defines a local control strategy that
satisfies the constraints while minimizing the cost J(θ).
Γ generator: we suppose that we have a generator
of sets Γ with a parametrized geometry providing a
family of nested potential sets Γ, then we can compute
the biggest one that is probabilistically certified through
(8).
Therefore, starting from Ω0 which is known to be
in the region of attraction of the desired equilibrium,
an iterative procedure can be designed to generate the
sequence {Ωk}
NC
k=0 such that the trajectories starting in
Ωk+1 end in
k⋃
j=0
Ωj with the desired probability and
without violating the constraints. In particular, we will
consider sequences of sets such that Ωk ∩ Ωk+1 = ∅.
Then we keep doing this certification process until, given
Ωk−1, the set Ωk is empty. Once the RoA probabilistic
certification algorithm terminates, the probabilisitically
certified RoA is the set ΩC =
NC⋃
i=1
Ωi.
Note that, if x0 ∈ Ωk for k = 1, · · · , NC , this means
that the trajectory of length T will end in
k−1⋃
j=0
Ωj without
violating the constraint with a certain probability, but
no direct probabilistic guarantee is given regarding the
convergence to the set Ω0. It is not straightforward to
derive a probabilistic bound on driving the states directly
from the last set of the sequence ΩNC to Ω0. This because
it involves the accuracy and confidence parameters, η and
δ, but also since there is no guarantee that, given the
initial state distribution X0(Ωk), the distribution of the
state at the end of the k-th therapeutic cycle is X0(Ωk−1),
for which the probabilistic validation is performed. How-
ever, after deriving the sequence of certified sets, we can
approximate the probability of driving the states from
ΩNC to Ω0, with the derived certified control strategy,
using Monte-Carlo simulations.
Algorithm 1 Sequence of probabilistically certified sets
Input: Ω0
k ← 0
while Ωk 6= ∅ do
Ω←
k⋃
j=0
Ωj
repeat
Generate Γ
until (8) is unfeasible for Γ
k ← k + 1
Ωk ← Γ
end while
NC ← k − 1
Output: ΩC ←
NC⋃
i=0
Ωi
Finally, by using Algorithm 1, we can obtain a se-
quence of certified sets, such that the output is the
probabilistically certified RoA ΩC .
IV. Probabilistically certified RoA for
cancer model
In cancer treatment, therapies are usually injected
following many successive cycles with specific periods
of hospitalization and rest. This makes the certification
framework presented in the previous section suitable to
certify RoAs for a cancer model. Hence, considering NC
treatment cycles, our objective consists of estimating the
probabilistically certified RoA of model (1) that we de-
note ΩC . To this end, we certify a sequence of successive
disjoint sets such that their union is the probabilistically
certified RoA. Moreover, the temporal control profiles
that we consider correspond only to the hospitalization
period (see Fig. 2), meaning that the rest period is not
included in the decision variable θ defined in Section II,
since we assume that this parameter can be estimated
afterwards depending on the health conditions of the
patient.
The initial condition x0 is assumed to be uniformly
distributed in the set Γ while the parameters of model (1)
are assumed to be normally distributed in the intervals
[0.9pnom, 1.1pnom], where pnom is the nominal value of
each parameter and the variance of these distributions is
0.01. The parameter x∞ is supposed to be known and
doesn’t follow any distribution.
The failure indicator function, which indicates whether
the constraints (3) are satisfied or not, is defined on
x(t|x0, p, θ) which is the state trajectory of (1) for a given
control parametrization θ and a random sample of x0
and p. We denote by x(T |x0, p, θ) the state trajectory
x evaluated at the end of the hospitalization period.
Therefore, the failure indicator is defined as:
g(θ, x0, p,Ω) :=


0 if x2(t|x0, p, θ) ≥ c ∀t
and x(T |x0, p, θ) ∈ Ω
1 otherwise
where Ω is a probabilistically certified target set which
can be seen as the safe region. Using Algorithm 1, we
can derive a sequence of probabilistically certified sets
providing the probabilistically certified RoA. Firstly, we
need to derive an initial target set Ω0, in order to
initialize the certification algorithm.
A. Probabilistically certified initial target set Ω0
We define the probabilistically certified initial target
set Ω0 as being the uncontrolled probabilistically certified
region of attraction of many locally asymptotically stable
equilibriums. Therefore, given p ∈ P (drawn according
to the probability distribution P) and x0 following a
uniform distribution on Ω0, that we denote U(Ω0), we
certify that:
PrU(Ω0)×P {x2(t|x0, p) ≥ c, ∀t > 0 ∧ x(T |x0, p) ∈ Ωeq} > 1− η,
(9)
for a given time T . We denote by Ωeq a certified set in a
neighborhood of benign equilibriums of (1), generated
by the realizations of p according to the probability
distribution P . Therefore Ωeq is derived such that:
PrU(Ωeq)×P {x2(t|x0, p) ≥ c, ∀t > 0 ∧ x(T |x0, p) ∈ Ωeq} > 1− η,
(10)
Note that Ωeq is slightly different than a probabilistically
certified invariant set, since we don’t require that the
trajectories starting in Ωeq stay in it, we rather require
that these trajectories satisfy the constraints (3) and
converge to Ωeq after some time T . Moreover, the set
Ωeq is derived in order to be used as a target set for the
determination of Ω0.
In order to find Ωeq, we draw the distribution of the
benign equilibriums of model (1) when it is subjected to
parametric uncertainties. Then, we choose a geometry for
Ωeq surrounding the benign equilibriums of the sample
shown in Fig. 4. Finally, we expand this set until (10) is
not satisfied. Fig. 4 shows the probabilistically certified
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Fig. 4: Probabilistically certified sets Ω0 for different times T
RoA of benign equilibriums Ωeq, the estimated uncon-
trolled nominal region of attraction ΩN and the initial
probabilistically certified target set Ω0 for different T .
Using the phase-portrait of system (1) with u = 0 and
considering nominal parameters (in Table I), we give an
estimate of the nominal region of attraction of the benign
equilibrium for system (1) without control, denoted ΩN ,
see Fig. 4. After finding a proper geometry for the set
Ωeq such that it satisfies (10), we use the transition be-
tween (7) and (8) provided by the randomized methods,
in order to certify the set Ω0. Note that in this case
X0(Γ) corresponds to U(Ω0) since we assume that x0
is uniformly distributed on Ω0, and the target set for
the states at time T denoted Ω in the definition of g
corresponds to Ωeq. Furthermore, since we deal with an
uncontrolled problem, we have that θ = 0, therefore, (7)
turns out to be a feasibility problem, where we need only
to guarantee the probability condition in (9) by using
the empirical mean over g for N i.i.d. samples of (x0, p)
mentioned in (8), with θ = 0 and nθ = 1, the bound N
is then given by Theorem 1.
Therefore, we assume that the set Ω0 to be certified
has the same geometry as the estimated nominal uncon-
trolled region of attraction ΩN that we shrink until (9) is
not satisfied given the confidence probability 1−δ. There
is clearly no guarantee that the set Ω0 that we obtain is
the biggest possible certified set, however, in this case,
proving the existence of a set Ω0 satisfying (9) is enough,
since Ω0 is only used as a target set for the Algorithm 1
allowing therefore to compute the sequence of certified
sets.
B. Probabilistically certified region of attraction ΩC
We denote by ΩC the probabilistically certified region
of attraction of system (1). We initialize Algorithm 1
with Ω0 in order to derive the sequence of probabilis-
tically certified sets providing the certified RoA for
model (1).
We consider that the decision variable θ is defined by
the following variables:

σI ∈ {0, 0.16, 0.32, 0.48, 0.64, 0.8},
σC = 0.2, νC = 0.2,
dI ∈ {0, 0.25, 0.5, 0.75, 1},
d¯C ∈ {0, 0.11, 0.22, 0.33, 0.44, 0.56, 0.67, 0.78, 0.89, 1},
where d¯C denotes the maximal desired concentration of
x3 allowing to monitor dC . Therefore, the cardinality of
Θ is nΘ = 300 giving the bound N ≥ 1863 according to
Theorem 1, for η = 10−2 and δ = 10−3. The number of
simulations to be performed for each set certification is
Nsim = N · nΘ = 558900. The required computational
time to performNsim simulations is around 5.79mn using
Matlab coder toolbox, therefore, 1 simulation requires
around 621µs on an hp EliteBook 2.60GHz Intel Core
i7.
Fig. 5 shows the 3 certified cycles for T = 5 ob-
tained using Algorithm 1, nominal and robust RoAs
that have been estimated using a sliding-mode-based
method, where bang-bang feedback control is considered.
We can see that, as the number of cycles increases, the
certified RoA gets closer to the robust controlled one.
Furthermore, it is interesting to notice that there is a
small region of Ω3, which is probabilistically certified but
does not belong to the robust RoA, although the control
structure in the robust case is less restrictive. This is
potentially due to the fact that the probabilistic method
is less conservative than the robust one. Furthermore, we
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Fig. 5: Probabilistically certified RoAs for 3 injection cycles
approximated the probability of driving the states from
Ω3 to Ω0 using 5000 Monte-Carlo simulations. We ob-
tained that 99.6% of the trajectories of (1) having initial
conditions in Ω3 converge to Ω0 using the probabilistic
certified control strategies that we derived.
V. Conclusion
In this paper, we presented a framework of proba-
bilistic certification for regions of attraction. This frame-
work is based on the randomized methods which allow
to overcome the conservatism of worst-case robust ap-
proaches by proposing a tractable problem with proba-
bilistic constraints. The framework of region of attraction
certification can be seen as a tool to tune the several
parameters of treatment protocols by properly choosing
the model parameters and their distributions, the geom-
etry of the regions of attraction to be certified and the
control parametrization. An interesting perspective for
future work would be to apply this methodology to other
systems describing cancer dynamics.
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